Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis

Bo Wang, Zijian Wang, Lizhi Han, Song Gong, Yanxue Wang, Zhiwen He, Yong Feng, Zhaohui YangCancer 2019 · DOI

Abstract

This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.

Introduction

The cell cycle is the fundamental process by which cancer cells proliferate, driven by "engines" known as cyclins. While cyclin D1 and D2 are well-established proto-oncogenes linked to poor patient outcomes, the prognostic role of cyclin D3 has remained controversial. Previous studies yielded conflicting results, with some suggesting a strong link to survival and others finding no significant association. This meta-analysis synthesizes data from over 2,300 patients to clarify whether cyclin D3 expression can reliably serve as a prognostic biomarker across various malignancies.

Methods and Study Selection

The researchers conducted a systematic review following standard guidelines for cancer biomarker trials, searching EMBASE, PubMed, and Web of Science for studies published up to July 2018. Inclusion criteria required pathologically diagnosed malignancy, measurement of cyclin D3 levels in tissue samples, and sufficient data to calculate Hazard Ratios (HR) and 95% Confidence Intervals (CI).

Fig. 1: Flow diagram of the study selection process, illustrating the transition from 276 identified records to 13 included full-length articles.

The final analysis pooled data from 13 eligible studies encompassing 16 cohorts and 2,395 participants. The malignancies represented included lymphoma, breast cancer, bladder cancer, laryngeal squamous cell carcinoma, ovarian adenocarcinomas, malignant melanoma, non-small cell lung cancer, renal cell carcinoma, and hepatocellular carcinoma. Statistical analysis was performed using Stata 14.0, employing random-effects models where high heterogeneity ($I^2 > 50\%$) was detected.

Key Results: Overall Survival

The primary finding of this meta-analysis is that high cyclin D3 expression is a significant predictor of poor Overall Survival (OS). Patients with elevated cyclin D3 levels faced a significantly higher risk of death, with a pooled HR of 1.88 (95% CI 1.31–2.69).

Fig. 2: Forest plot showing the meta-analysis of the pooled HR of OS for malignancy patients, indicating a significant overall risk associated with high cyclin D3 expression.

Beyond OS, the study found that high expression was even more strongly linked to Disease-Specific Survival (DSS) (HR 2.68; 95% CI 1.35–5.31). Subgroup analysis revealed that the association was most potent in lymphoma (HR 3.72), suggesting cyclin D3 plays a particularly pivotal role in the pathogenesis of hematological malignancies. In non-lymphoma solid tumors, the correlation remained significant but less intense (HR 1.51).

Discussion and Clinical Insights

While cyclin D3 strongly predicts the lethality of the disease (OS and DSS), it did not show a statistically significant link to Disease-Free Survival (DFS) or Progression-Free Survival (PFS) in this dataset. This suggests that cyclin D3 may be more indicative of aggressive tumor progression and ultimate mortality rather than the timing of initial recurrence.

Interestingly, no significant link was found between cyclin D3 and OS in breast cancer specifically. This discrepancy might be due to the inclusion of mostly early-stage (I-III) cases in the source studies, suggesting that the protein's prognostic value could be stage-dependent.

Limitations and Future Directions

Despite the clear overall trend, the analysis noted high heterogeneity ($I^2 = 76.2\%$) across studies, likely stemming from diverse cancer types and varying sample sizes. Furthermore, there is currently no standardized threshold for "high" vs. "low" cyclin D3 expression; studies used cut-offs ranging from >5% to >50% positive cells.

Future research should focus on larger-scale, multicenter prospective studies using standardized staining protocols to confirm these findings and better define the role of cyclin D3 across different clinical stages of cancer.

Summary updated

Abstract

This meta-analysis demonstrated that highly expressing cyclin D3 might be an unfavorable prognostic biomarker for various malignancy patients, which can make great contributions to the clinical diagnosis and treatment.
BibTeX
@inproceedings{wang2019prognostic,
  author = {Bo Wang and Zijian Wang and Lizhi Han and Song Gong and Yanxue Wang and Zhiwen He and Yong Feng and Zhaohui Yang},
  title = {{Prognostic significance of cyclin D3 expression in malignancy patients: a meta-analysis}},
  booktitle = {Cancer},
  year = {2019},
  doi = {10.1186/s12935-019-0865-3},
}
Figure